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Minneapolis, Minnesota).Background There is an increasing interest in transcatheter mitral valve (MV) treatment. The NeoChord DS 1000 system enables
off-pump beating heart transapical MV repair with implantation of artiﬁcial neo-chordae.Methods Patients with severemitral regurgitation (MR) due to isolated posterior prolapse were included in this TACT (Transapical
Artiﬁcial Chordae Tendinae) trial. All patients were scheduled for off-pump transapical implantation of neo-chordae.Results Thirty patients at 7 centers were enrolled. Major adverse events included 1 death due to post-cardiotomy syndrome
and concomitant sepsis and 1 minor stroke with the patient fully recovered at the 30-day follow-up visit. Additional
patients experienced procedural major adverse events related to a reoperation or conversion to standard of care.
Acute procedural success (placement of at least 1 neo-chord and reduction of MR from 3þ or 4þ to 2þ) was
achieved in 26 patients (86.7%). In 4 patients neo-chordae were not placed for technical and/or patient-speciﬁc
reasons. These patients underwent intraoperative (3 patients) or post-operative (1 patient) standard MV repair. At 30
days, 17 patients maintained an MR grade 2þ. Four patients who developed recurrent MR were successfully
treated with open MV repair during 30-day follow-up. Results improved with experience: durable reduction in MR
to 2þ at 30 days was achieved in 5 (33.3%) of the ﬁrst 15 patients and 12 (85.7%) of the last 14 patients.Conclusions Off-pump transapical implantation of artiﬁcial chordae to correct MR is technically safe and feasible; however, it
yields further potential for improvement of efﬁcacy and durability. (Safety and Performance Study of the NeoChord
Device [TACT]; NCT01777815) (J Am Coll Cardiol 2014;63:914–9) ª 2014 by the American College of Cardiology
FoundationSurgical mitral valve (MV) repair with the use of artiﬁcial neo-
chordae for Carpentier type II pathology has proven excellent
short- and long-term results (1–6). A newly developed
device (NeoChord DS1000 system, NeoChord, Inc., Min-
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3; revised manuscript received June 24, 2013,neo-chordae to correct mitral regurgitation (MR) on the
beating heart without cardiopulmonary bypass (7). This
approach may be of special value to correct degenerative
MR for prolapse; however, clinical applicability has not yet
been investigated. After thorough pre-clinical and ﬁrst-in-
man application the investigation of this new treatment was
performed (7–9).We herein report on the very early results of
the TACT (Transapical Artiﬁcial Chordae Tendinae) study.Methods
Study design and endpoints. A prospective, multicenter,
single-arm study with pre-deﬁned endpoints was performed
to evaluate the safety and performance of the NeoChord
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915DS1000 system (Fig. 1, Table 1). Patients were seen at 30 days
post-procedure for study endpoints.
Patient selection. Patients with severe MR due to isolated
Carpentier type II prolapse of the posterior MV leaﬂet and
no annulus dilation (NeoChord, Inc.), with an indication for
surgery conﬁrmed according to guidelines, were included in
the trial (1,10). Key exclusion criteria included secondary
MR, severe left ventricular dysfunction (left ventricular
end-diastolic diameter >6.5 cm), anterior or bileaﬂet MV
prolapse, permanent atrial ﬁbrillation, and concomitant
cardiac disease with an indication for surgical treatment.
Ethics approval. Informed consent was obtained from all
patients prior to surgery. All patients were informed about
the ﬁrst-in-human nature of this study. Ethics committee
approval was granted by the respective institutional review
boards. Leading ethics committees were Aarhus (Den-
mark), Leipzig (Germany), Turin (Italy), and Vilnius
(Lithuania).
Operative setup. Patients were prepared for surgery
according to the respective standard of care (SOC) of each
participating center. SOC general anesthesia was performed
and SOC equipment was available in all cases if necessary.
In all patients the safety net strategy was chosen using
femoral lines for potential cardiopulmonary bypass cannu-
lation. Cell saver with blood retransfusion was prepared for
use in all patients.
Surgical technique. The NeoChord procedure was per-
formed under 2-dimensional and 3-dimensional trans-
esophageal echocardiographic guidance through a standard
transapical access as previously described (Fig. 2) (7). In
brief, the NeoChord DS 1000 device enables implantation
of neo-chordae using polytetraﬂuoroethylene sutures to the
prolapsing MV leaﬂet. After grasping of the MV leaﬂet
tissue with 2 grippers, embedded color-sensible ﬁber optics
allow for veriﬁcation of sufﬁcient tissue grasping. Piercing
and ﬁxation with subsequent retraction of the neo-chordae
are realized using a special needle. After a girth hitch knot
is tied and slid to the leaﬂet, the 2 free ends of the suture are
then ﬁxed on the left ventricular apex at a deﬁned length for
correction of leaﬂet prolapse (Fig. 3). Procedures wereFigure 1 NeoChord DS1000 Device for Transapical Off-Pump Implant
(A) The NeoChord DS1000 device (NeoChord, Inc., Minneapolis, Minnesota) which conta
valve leaﬂet tissue, and a long shaft with the grasping mechanism on the very tip. (B) Th
tissue color (red for blood, white for mitral valve leaﬂet tissue) within the graspers to verify
this initial clinical trial.performed by 6 senior surgeons
in cooperation with two lead
surgeons (proctor).
Data acquisition. Data were
prospectively collected by the
respective study coordinator at
each participating center. Pre-
and post-operative echocardiog-
raphy core laboratory analysis
was performed (Mayo Clinic,
Rochester, Minnesota). The trial
was monitored by an independent contract research orga-
nization. A Clinical Events Committee reviewed and adju-
dicated all serious adverse events.
Statistical analysis. Data are presented as descriptive
statistics where the distribution (number and percent) is
reported for each level of the categorical response along
with the 95% exact conﬁdence interval. Summary statistics
(n, mean, median, SD, minimum, and maximum) are re-
ported for continuous variables.
Results
Patient characteristics. A total of 30 patients at 7 centers
were enrolled in the TACT trial. All patients presented
with severe MR due to isolated prolapse of the posterior
mitral leaﬂet (PML). Relevant patient variables as well as
concomitant diseases are depicted in Table 2.
Procedure reﬁnements. Two procedure reﬁnements were
introduced during the conduct of the trial: 1) the use of
multiple neo-chordae per procedure (introduced after 2
patients received implants); and 2) the revision of the left
ventricular access to a posterolateral approach (introduced
after 15 patients received implants). Therefore data will be
presented in the following cohorts:
 Entire cohort: all patients enrolled (n ¼ 30)
 Multiple suture cohort: patients in whom multiple
sutures were recommended (n ¼ 28)
 Posterolateral cohort: patients undergoing implan-
tation with a posterolateral apical access (n ¼ 15)ation of Artiﬁcial Chordae Tendinae
ins a handle for steering purpose, the needle, which is advanced through the mitral
e associated device monitor, which contains ﬁber optics that reﬂect the respective
a successful leaﬂet grasp. The device has proven user-friendliness and efﬁcacy within
Table 1
Study Endpoints for Safety and Performance of the
NeoChord DS1000 Device* for Treatment of
Mitral Regurgitation Due to Isolated Posterior
Leaﬂet Prolapse
Primary safety endpoints
(30 days)
Major adverse events
 Death
 Myocardial infarction
 Reoperation for failed surgical repair
 Nonelective cardiovascular surgery to treat
an adverse event
 Procedural ventilation >48 h
 Procedure-related transfusion of >2 U blood
product
 Stroke
 Renal failure
 Deep wound infection
 New onset of permanent atrial ﬁbrillation
 Septicemia
Primary performance
endpoints (30 days)
 Rate of patients maintaining mitral regurgi-
tation reduction grade 2
*Trademark of NeoChord, Inc., Minneapolis, Minnesota.
Figure 3
Artiﬁcial Chordae Tendinae 6 Months
After Implantation
Six-month follow-up transthoracic control echocardiography in a patient who
underwent successful transapical off-pump implantation of neo-chordae to correct
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916Safety. Eight (26.7%) patients experienced at least 1 major
adverse event (MAE) during the ﬁrst 30 days (Table 3). Six
patients underwent conversion to successful SOC MV
repair: 2 patients experienced early dehiscence of neo-
chordae as both received implantation of just 1 neo-chord.
These early dehiscences resulted in procedure modiﬁcation
1 (single to multiple neo-chordae). Two additional patients
experienced early dehiscence and were converted to SOC.
Two patients did not have acute procedural success (APS)Figure 2
Intraoperative Imaging With 3-Dimensional
Transesophageal Echocardiography
This intraoperatively taken 3-dimensional transesophageal echocardiography
image depicts the very tip of the NeoChord DS1000 device (NeoChord, Inc.,
Minneapolis, Minnesota) (arrow) within the mitral valve oriﬁce. The grasping
mechanism, which can be identiﬁed as the accentuation on the tip, is facing the
posteromedial commissure. Three-dimensional echocardiography imaging is
especially valuable for identiﬁcation of the prolapsing segment of the mitral valve
as well as for intraoperative navigation of the device. AML ¼ anterior mitral leaﬂet;
PML ¼ posterior mitral leaﬂet.
posterior mitral leaﬂet prolapse is shown. The artiﬁcial neo-chord can be identiﬁed
as the string (arrow) from the left ventricular apex toward the coaptation zone
between the PML and AML. Echocardiographic control exams at 6 months post-
operation underline the intermediate-term durability of this innovative repair
technique. Abbreviations as in Figure 2.and were converted to SOC (1 intraoperative and 1 post-
operative).
One patient died within 30 days due to post-cardiotomy
syndrome and concomitant sepsis. This patient was an
82-year-old female with signiﬁcant comorbidities who
developed recurrent MR on post-operative day 4. One
patient (3.3%) experienced perioperative minor stroke with
full recovery at the 30-day follow-up visit. Of note, no
patient experienced intraoperative hemodynamic deteriora-
tion and/or resuscitation.
Acute procedural success. APS, deﬁned as placement of at
least 1 neo-chord and reduction of MR to 2þ, was ach-
ieved in 26 patients (86.7%). In 4 patients, neo-chordae
were not placed for technical or patient-speciﬁc reasons,
and thus these patients underwent subsequent successful
MV repair (Fig. 4). In 2 other patients, neo-chordae
dehisced under minimal tensioning load due to poor tissue
quality; both patients were intraoperatively converted to
SOC. In 1 patient 2 neo-chordae were successfully deployed;
however, a perforation of the PML dictated intraoperative
conversion. In 1 patient, multiple attempts to place neo-
chordae were unsuccessful and conversion to SOC was
Table 2 Baseline Data of the 30 Patients in the TACT
Age, yrs 63.5  11.9
Female 12 (40.0)
BMI, kg/m2 25.7  3.7
LVEF, % 59  5
MR grade 3þ 3 (10.0)
MR grade 4þ 27 (90.0)
PML prolapse 30 (100)
PML chordae rupture and/or chordae elongation 30 (100)
NYHA functional class II 13 (43.3)
NYHA functional class III 17 (56.6)
Hyperlipidemia (medically treated) 3 (10.0)
Arterial hypertension 16 (53.3)
Coronary artery disease 1 (3.3)
Prior myocardial infarction 0 (0)
Prior percutaneous coronary intervention 2 (6.7)
Intermittent atrial ﬁbrillation 3 (10.0)
Prior stroke 0 (0)
Pulmonary hypertension 10 (33.3)
COPD 1 (3.3)
Diabetes mellitus 3 (10.0)
Malignancy 3 (10.0)
Values are mean  SD or n (%).
BMI ¼ body mass index; COPD ¼ chronic obstructive pulmonary disease; LVEF ¼ left ventricular
ejection fraction; MR ¼ mitral regurgitation; NYHA ¼ New York Heart Association; PML ¼ posterior
mitral leaﬂet.
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917performed 7 days post-procedure. All 4 patients received
successful MV repair (Fig. 4). With the procedural modi-
ﬁcations in the last 15 patients (posterolateral cohort), APS
reached 100% (Table 4).
30-day results. The 30-day follow-up visits have been
completed on all patients. At 30 days, 17 of 29 (58.6%)
maintained performance success. Of these 17 patients, 12
(71%) have maintained an MR grade 1þ. One patient
had an indeterminate result at the 30-day visit and is
therefore not included in the 30-day success rate. The
overall success rate improved with each additional suture
placed (Fig. 5).Table 3
MAEs in the Entire Patient Cohort as We
Implantation Through a Posterolateral Ap
Any MAE
Death (post-cardiotomy syndrome with subsequent sepsis)
Reoperation for failed repair*
Procedure-related transfusion >2 U of blood
Procedural ventilation >48 h
Stroke (transient)
Myocardial infarction
Nonelective cardiovascular surgery
Renal failure
Deep wound infection
New onset of permanent atrial ﬁbrillation
Septicemia
Values are n (%). *One patient was intraoperatively converted to standard
standard of care procedure required a modiﬁcation. Numbers are not mutuDiscussion
The TACT trial shows the feasibility, safety, and efﬁcacy of
off-pump transapical implantation of neo-chordae using the
NeoChord DS1000 system to correct MR.
Concept. The concept of off-pump transapical implanta-
tion of neo-chordae to the mitral leaﬂet with apical ﬁxation
has been introduced and evaluated in pre-clinical trials (9).
The technology is based on 2 principles: 1) the very broad
and excellent experience with surgical implantation of neo-
chordae using expanded polytetraﬂuoroethylene sutures;
and 2) the secure and standardized transapical left ventric-
ular access (4,6,9,11,12).
The DS1000 device includes potential advantages over
conventional open MV repair. The technology enables
resuspension of a prolapsed PML under physiological
conditions on the beating heart without the use of cardio-
pulmonary bypass and its inherit risks of morbidity and
mortality. As shown herein, perioperative morbidity and
mortality using the DS1000 system are low despite the very
early stage of development and clinical application.
Clinical results. MAEs related to an intra- or post-
operative conversion to SOC. There was 1 death due to
post-cardiotomy syndrome, concomitant sepsis, and multi-
organ failure. This multimorbid patient, however, who was
on inotropic support before the procedure, was considered a
high-risk candidate. During surgery, anatomical challenges
further complicated the case, and in retrospect the inclusion
of this patient was rated as selection failure. Additional mor-
bidity of the procedure was low, with 1 transient stroke.
Prolonged post-operative respiratory support was necessary
in only 1 patient (the same patient who died). The majority
of patients were extubated within 3 h post-operatively. The
amount of procedure-related transfusion was very reasonable.
Learning curve. Through the course of the study, APS,
durability, and safety signiﬁcantly improved. As previously
mentioned, 2 procedure reﬁnements (1 and 2) were intro-
duced during the conduct of the trial. We explain thell as in the Latter 15 Patients Who Underwent
proach
Entire Cohort
(n ¼ 30)
Posterolateral Approach
(n ¼ 15; Patients #16 to #30)
8 (26.7) 1 (6.7)
1 (3.3) 0 (0.0)
6 (20.0) 1 (6.7)
5 (16.7) 1 (6.7)
1 (3.3) 0 (0.0)
1 (3.3) 0 (0.0)
0 (0.0) 0 (0.0)
0 (0.0) 0 (0.0)
0 (0.0) 0 (0.0)
0 (0.0) 0 (0.0)
0 (0.0) 0 (0.0)
0 (0.0) 0 (0.0)
of care, but adjudicated as a major adverse event (MAE) because the
ally exclusive because 1 patient can experience more than 1 MAE.
Figure 4 The TACT Study Flow Chart
A ﬂow chart of the Transapical Artiﬁcial Chordae Tendinae (TACT) trial is depicted. From a total of 30 attempted procedures, 26 were performed successfully, whereas in 4
patients there was no APS achieved. Early echocardiographic follow-up identiﬁed mitral regurgitation (MR) graded as 2þ or less in 17 patients. Despite the acute/late conversion
to standard of care (SOC) in 4 of 4 patients the overall success rate is acceptable with regard to the procedural aspects. Long-term durability, however, remains unknown.
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918observed improvements as the following: 1) the equal
distribution of mechanical stress on MV leaﬂet tissue and
polytetraﬂuoroethylene sutures when using multiple neo-
chordae; and 2) the reduction of mechanical stress due to
the posterolateral ﬁxation of neo-chordae.
Special consideration was given to optimal patient
selection with regard to MV leaﬂet morphology. Initially,
only patients with narrow prolapsing segments were
considered to be suitable; however, these patients have
shown an even higher difﬁculty with secure grasping and
placement of neo-chordae. In consequence, patients with
a wide P2 and/or P3 prolapse were identiﬁed as most
suitable, and best results were achieved in these patients
with regard to acute and durable reduction of MR.
Perspective. Despite the encouraging results of this study
using the new NeoChord DS1000 device, the SOC for
patients with secondary MR is and will remain surgical open
MV repair (1,3,6,11). Catheter-based and innovative
approaches may represent a signiﬁcant potential for inno-
vation to treat MV disease in the future; however, they so far
only reﬂect a niche in clinical practice and are generally
accepted to offer palliation rather than treatment.
The NeoChord approach, however, with its promising
initial results, may become a treatment option in patientsTable 4
Post-Procedure MR 2þ and 30-Day MR 2þ Results for the
Multiple Neo-Chordae, and Patients Who Underwent the Pro
Parameter
Entire Cohort
(n ¼ 30)
n/N % 95% CI n/N
Post-procedure MR 2þ 26/30 86.7 69.3–96.2 24/28
30-day MR 2þ* 17/29 58.6 39.0–76.5 17/27
*One patient with an indeterminate mitral regurgitation (MR) grade at 30 days is excluded from the 30
CI ¼ conﬁdence interval.with isolated MV leaﬂet prolapse: the physiological ap-
proach, the low invasiveness, and the effective reduction of
MR at a very low operative risk may be used in the very
early disease process of primary MR.
Therefore, however, the somewhat preliminary results of
this study need to be completed, especially with regard to
durability in a large clinical surveillance study.
Study limitations. This study represents the ﬁrst-in-man
clinical experience with transapical off-pump implantation of
neo-chordae to correct MR and thus only preliminary
conclusions can be drawn from the results. The determination
of the exact positioning, length adjustment, and neo-chordae
tensioning depends exclusively on the ability and training of
the operator and echocardiographer. The exact ﬁxation of
neo-chordae on the posterolateral wall is of special interest
because it has improved the APS as well as durability; thus,
special and extensive training is inevitable.
Conclusions
MV repair for PML prolapse with off-pump transapical
implantation of neo-chordae is safe and feasible from
a procedural point of view. Further investigation is needed to
assess durability and long-term outcome.Entire Cohort of Patients, Patients Who Underwent Implantation of
cedure Using a Posterolateral Approach on the Cardiac Apex
Multiple Sutures
(n ¼ 28)
Posterolateral
(n ¼ 15)
% 95% CI n/N % 95% CI
85.7 67.3–96.0 15/15 100 78.2–100.0
63.0 42.3–80.6 12/14 85.7 57.2–98.2
-day results.
Figure 5
Acute Procedural Success Rate in Relation to the
Number of Implanted Artiﬁcial Chordae
Within the course of the TACT trial, 2 procedure reﬁnements were introduced: the
use of multiple neo-chordae per procedure and the revision of the left ventricular
apical assess site toward the posterolateral wall. The impact of the use of multiple
neo-chordae on the 30-day success rate in patients undergoing off-pump trans-
apical mitral valve repair is shown herein: the more neo-chordae implanted, the
higher the 30-day success rate. Although adequate data are lacking, this may well
be attributed to the decreased forces applied to each single neo-chord in this
multiple neo-chordae approach.
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